CON: Carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales

被引：19

作者：

Rodriguez-Bano, Jesus ^{[1
,2
,3
]}

Gutierrez-Gutierrez, Belen ^{[1
,2
,3
]}

Pascual, Alvaro ^{[1
,2
,4
]}

机构：

[1] Hosp Univ Virgen Macarena, Unidad Clin Enfermedades Infecciosas Microbiol &, Seville, Spain

[2] Inst Biomed Sevilla IBiS, Seville, Spain

[3] Univ Seville, Dept Med, Seville, Spain

[4] Univ Seville, Dept Microbiol, Seville, Spain

来源：

JAC-ANTIMICROBIAL RESISTANCE | 2021年 / 3卷 / 01期

关键词：

BLOOD-STREAM INFECTIONS; ESCHERICHIA-COLI; PIPERACILLIN-TAZOBACTAM; KLEBSIELLA-PNEUMONIAE; EFFICACY; ANTIBIOTICS; SAFETY;

D O I：

10.1093/jacamr/dlaa112

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Carbapenems are considered the drugs of choice for the treatment of serious infections caused by ceftriaxoneresistant Enterobacterales. However, because of the dramatic increase in carbapenem-resistant organisms worldwide, finding alternatives to carbapenems is a must. The potential options include beta-lactam/beta-lactamase inhibitor combinations, temocillin, cephamycins and some non-beta-lactamdrugs. The most controversial is piperacillin/tazobactam; the results of the MERINO trial are challenged because the isolates of patients with worse outcomes were frequently not susceptible to piperacillin/tazobactam when studied by reference methods, and also because the drug was not administered in extended infusion. Other potential options are briefly discussed. We conclude that carbapenems are not necessary for all patients with infections caused by ceftriaxone-resistant Enterobacterales.

引用

页数：4

共 22 条

[1]

Andersen MG, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.02306-17, 10.1128/aac.02306-17]

[2] Carbapenemase-Producing Organisms: A Global Scourge [J].

Bonomo, Robert A. ;

Burd, Eileen M. ;

Conly, John ;

Limbago, Brandi M. ;

Poirel, Laurent ;

Segre, Julie A. ;

Westblade, Lars F. .

CLINICAL INFECTIOUS DISEASES, 2018, 66 (08) :1290-1297

[3] Antibiotic resistance - Squeezing the balloon? [J].

Burke, JP .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (14) :1270-1271

[4] Renal safety of a single dose of gentamicin in patients with sepsis in the emergency department [J].

Cobussen, M. ;

Haeseker, M. B. ;

Stoffers, J. ;

Wanrooij, V. H. M. ;

Savelkoul, P. H. M. ;

Stassen, P. M. .

CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (05) :717-723

[5] Inoculum Effect on the Efficacies of Amoxicillin-Clavulanate, Piperacillin-Tazobactam, and Imipenem against Extended-Spectrum β-Lactamase (ESBL)-Producing and Non-ESBL-Producing Escherichia coli in an Experimental Murine Sepsis Model [J].

Docobo-Perez, F. ;

Lopez-Cerero, L. ;

Lopez-Rojas, R. ;

Egea, P. ;

Dominguez-Herrera, J. ;

Rodriguez-Bano, J. ;

Pascual, A. ;

Pachon, J. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (05) :2109-2113

[6] Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients [J].

Gutierrez-Gutierrez, B. ;

Rodriguez-Bano, J. .

CLINICAL MICROBIOLOGY AND INFECTION, 2019, 25 (08) :932-942

[7]

Gutierrez-Gutierrez B, 2016, Antimicrob Agents Chemother, V60

[8] Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial [J].

Harris, Patrick N. A. ;

Tambyah, Paul A. ;

Lye, David C. ;

Mo, Yin ;

Lee, Tau H. ;

Yilmaz, Mesut ;

Alenazi, Tamer H. ;

Arabi, Yaseen ;

Falcone, Marco ;

Bassetti, Matteo ;

Righi, Elda ;

Rogers, Benjamin A. ;

Kanj, Souha ;

Bhally, Hasan ;

Iredell, Jon ;

Mendelson, Marc ;

Boyles, Tom H. ;

Looke, David ;

Miyakis, Spiros ;

Walls, Genevieve ;

Al Khamis, Mohammed ;

Zikri, Ahmed ;

Crowe, Amy ;

Ingram, Paul ;

Daneman, Nick ;

Griffin, Paul ;

Athan, Eugene ;

Lorenc, Penelope ;

Baker, Peter ;

Roberts, Leah ;

Beatson, Scott A. ;

Peleg, Anton Y. ;

Harris-Brown, Tiffany ;

Paterson, David L. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (10) :984-994

[9] Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis [J].

Harris, Patrick N. A. ;

Wei, Jane Y. ;

Shen, Andrew W. ;

Abdile, Ahmed A. ;

Paynter, Stuart ;

Huxley, Rachel R. ;

Pandeya, Nirmala ;

Doi, Yohei ;

Huh, Kyungmin ;

O'Neal, Catherine S. ;

Talbot, Thomas R. ;

Paterson, David L. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (02) :296-306

[10] Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study [J].

Henderson, A. ;

Paterson, D. L. ;

Chatfield, M. D. ;

Tambyah, P. A. ;

Lye, D. C. ;

De, P. P. ;

Lin, R. T. P. ;

Chew, K. L. ;

Yin, M. ;

Lee, T. H. ;

Yilmaz, M. ;

Cakmak, R. ;

Alenazi, T. H. ;

Arabi, Y. M. ;

Falcone, M. ;

Bassetti, M. ;

Righi, E. ;

Rogers, B. A. ;

Kanj, S. S. ;

Bhally, H. ;

Iredell, J. ;

Mendelson, M. ;

Boyles, T. H. ;

Looke, D. F. M. ;

Runnegar, N. J. ;

Miyakis, S. ;

Walls, G. ;

Khamis, M. A., I ;

Zikri, A. ;

Crowe, A. ;

Ingram, P. R. ;

Daneman, N. ;

Griffin, P. ;

Athan, E. ;

Roberts, L. ;

Beatson, S. A. ;

Peleg, A. Y. ;

Cottrell, K. ;

Bauer, M. J. ;

Tan, E. ;

Chaw, K. ;

Nimmo, G. R. ;

Harris-Brown, T. ;

Harris, P. N. A. .

CLINICAL INFECTIOUS DISEASES, 2021, 73 (11) :E3842-E3850

← 1 2 3 →